



## Press release

### **Invitation to presentation of BioArctic's Interim Report for the period January – September 2019 on October 24 at 9.30 a.m. CET**

**Stockholm, Sweden, October 16, 2019** – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January – September 2019 on Thursday, October 24, 2019 at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on October 24, at 09:30 – 10:30 a.m. CET.

Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – September 2019 followed by a Q&A-session.

Sweden: + 46 8 505 583 56  
Denmark: + 45 781 501 09  
Germany: + 49 692 222 203 77  
The Netherlands: + 31 207 219 495  
Norway: + 47 235 002 43  
Switzerland: + 41 225 675 632  
UK: + 44 333 300 9267  
US: + 1 833 823 0589

Webcast: <https://tv.streamfabriken.com/bioarctic-q3-2019>

The webcast will afterwards also be available on demand at BioArctic's corporate website [www.bioarctic.com](http://www.bioarctic.com), Investors, Financial presentations.

#### **For more information, please contact:**

Jan Mattsson, CFO  
Telephone: + 46 70 352 27 72  
E-mail: [jan.mattsson@bioarctic.se](mailto:jan.mattsson@bioarctic.se)

#### **About BioArctic**

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet



medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). [www.bioarctic.com](http://www.bioarctic.com)

*This information was submitted for publication at 08:30 a.m. CET on October 16, 2019.*